Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
November 14 2024
Exciting research is being done in the burgeoning field called Metabolic Psychiatry, which is dedicated to addressing the bioenergetic underpinnings o...
JAMA Network Open recently published results of a randomized, open-label, active parallel-controlled clinical trial comparing an intermittent fasting program to both metformin and empagliflozin in Chinese adults with early type 2 diabetes. Known as the EARLY (Exploration of Treatment of Newly Diagnosed Overweight/Obese Type 2 Diabetes Mellitus) study, 405 participants were randomized in a 1:1:1 ratio to either metformin, empagliflozin, or the 5:2 MR, the latter consisting of 2 non-consecutive fasting days and 5 days of usual intake per week and meal replacement (MR) diet. Participants following the 5:2 MR had, within 1 week, 5 days of consuming their usual breakfast and lunch but a meal replacement for dinner, and on the 2 non-consecutive days, only consumed 1 meal replacement for a daily energy intake of 500 kcal for women and 600 kcal for men (on those 2 days). The 2 meal replacement formulations provided 17-20g of protein per serving, with ingredients including medium chain triglycerides, DHA, extra-virgin olive oil, etc.
The study was 16 weeks long with 8 weeks of additional follow-up; hemoglobin A1c (HbA1c) was the primary endpoint. The 5:2 MR approach was found to be superior to either drug in terms of glycemic control and weight loss. The HbA1c was reduced by 1.9% in this group, a significantly greater increase than either medication (e.g. metformin -1.6% and empagliflozin -1.5%). The 5:2 MR program also resulted in more significant and sustained reductions in weight loss and waist circumference; a weight loss of −9.7 kg with 5:2 MR versus −5.5 kg and -5.8 kg in the medication groups. There were similar improvements in fasting glucose and insulin, C-peptide levels, and HOMA-IR between groups, but more favorable changes in blood pressure, triglycerides, and HDL-C in the 5:2 MR group.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment